Wedbush Has Bullish Outlook for Zenas BioPharma Q3 Earnings

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Wedbush increased their Q3 2025 earnings per share (EPS) estimates for Zenas BioPharma in a report released on Tuesday, September 2nd. Wedbush analyst M. Fan now anticipates that the company will post earnings of $1.91 per share for the quarter, up from their previous forecast of ($1.33). Wedbush currently has a “Outperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas BioPharma’s Q4 2025 earnings at $1.49 EPS, FY2025 earnings at $1.37 EPS, Q1 2026 earnings at ($1.36) EPS, Q2 2026 earnings at ($1.37) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.40) EPS, FY2026 earnings at ($5.51) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($4.57) EPS and FY2029 earnings at ($2.73) EPS.

Several other analysts also recently weighed in on the company. Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Zenas BioPharma in a report on Friday, May 16th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $36.67.

Zenas BioPharma Price Performance

ZBIO stock opened at $20.51 on Friday. The company has a 50-day moving average price of $14.73. The company has a market capitalization of $863.68 million and a P/E ratio of -5.78. Zenas BioPharma has a 1-year low of $5.83 and a 1-year high of $26.25.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Hedge Funds Weigh In On Zenas BioPharma

Several hedge funds have recently modified their holdings of ZBIO. New York State Common Retirement Fund acquired a new position in shares of Zenas BioPharma during the first quarter valued at about $49,000. Jefferies Financial Group Inc. acquired a new position in shares of Zenas BioPharma during the first quarter valued at about $348,000. Nuveen LLC purchased a new stake in Zenas BioPharma in the first quarter valued at approximately $250,000. PNC Financial Services Group Inc. boosted its position in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after buying an additional 2,679 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.